TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16193675
Drug: Botulinum toxin‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin‐A injections (20 units in one single injection)
Study: 16193675
Drug: Botulinum toxin‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin‐A injections
Study: 12956915
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of two per cent lignocaine and adrenaline 1:200000 with 1500 IU hyaluronidase
Study: 12956915
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of two per cent lignocaine and adrenaline 1:200000
Study: 2070654
Drug: 5 percent
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 percent 5‐fluorouracil cream
Study: 27569737
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravenous ibuprofen injection (0.2g, 0.4g, 0.8g) administered as a 30-minute IV infusion.
Study: 27569737
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of intravenous ibuprofen (0.4g every 6 hours for 9 doses).
Study: 27569737
Drug: Tolerability assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerability assessment of intravenous ibuprofen.
Study: 24576858
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of fast‐acting β2‐agonist (BD)
Study: 22958874
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg dextromethorphan
Study: 20189608
Drug: Pulsatile insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile insulin infusion therapy
Study: 18514865
Drug: Multimodal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal oral pain medication protocol including preemptive oral analgesics, epidural anesthesia, pericapsular analgesic injection, and postoperative analgesia without parenteral opioids
Study: 18514865
Drug: Multimodal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal oral pain medication protocol
Study: 16230877
Drug: niacin extended-release/lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin extended-release/lovastatin 1000/40 mg
Study: 16230877
Drug: simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 10 mg and 20 mg
Study: 8706296
Drug: Intravenous beta-endorphin
Normalized name: beta-endorphin human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous beta-endorphin 5 mg/50 ml
Study: 1796228
Drug: Ivermectin 100
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 100 mcg/kg and DEC 3 mg/kg (twice a year)
Study: 1796228
Drug: Microfilaricidal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfilaricidal drugs
Study: 6849786
Drug: Solpadeine (paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solpadeine (paracetamol with codeine and caffeine)
Study: 6849786
Drug: Panadol (paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panadol (paracetamol alone)
Study: 6849786
Drug: Paramax (paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paramax (paracetamol with metoclopramide)
Study: 17638634
Drug: Bisacodyl suppository
Normalized name: bisacodyl Rectal Suppository
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bisacodyl suppository
Study: 12173729
Drug: Miglitol 25
Normalized name: miglitol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 25 mg t.i.d.
Study: 12173729
Drug: Miglitol 50
Normalized name: miglitol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 50 mg t.i.d.
Study: 12173729
Drug: Miglitol 100
Normalized name: miglitol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 100 mg t.i.d.
Study: 12173729
Drug: Miglitol 200
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol 200 mg t.i.d.
Study: 9452226
Drug: 8-drugs-in-1-day (8-in-1)
Normalized name: goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-drugs-in-1-day (8-in-1) chemotherapy followed by radiotherapy
Study: 9452226
Drug: 8 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 cycles of chemotherapy
Study: 7884950
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant treatment aimed at a target international normalized ratio of 2.8 to 4.8
Study: 7884950
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant treatment
Study: 192808
Drug: Intravenous adenine
Normalized name: Adenine
DrugBank: Adenine (DB00173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenine arabinoside (ara‐A)
Study: 30739540
Drug: Kinesiotaping (KT)
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Kinesiotaping (KT) plus routine COPD medical treatment
Study: 30739540
Drug: Routine COPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine COPD medical treatment
Study: 29197413
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of NOAC therapy (≤ 4 days after stroke onset)
Study: 29197413
Drug: Delayed initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed initiation of NOAC therapy (≥ 5-10 days after stroke onset)
Study: 23369879
Drug: 10mg amlodipine/80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg amlodipine/80mg atorvastatin (test product)
Study: 19473629
Drug: High-dose ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ARB (losartan 200 mg/day)
Study: 19473629
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose ARB (losartan 100 mg/day)
Study: 19473629
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose ACEI (20 mg/day)
Study: 19473629
Drug: Low-dose ACEI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ACEI (10 mg/day)
Study: 9519234
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 2 mg daily via metered-dose inhaler and Volumatic
Study: 8592675
Drug: Nefazodone (NEF)
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nefazodone (NEF) infused into the proximal intestine (400 mg over 5 hours)
Study: 8592675
Drug: Nefazodone (NEF)
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nefazodone (NEF) infused into the distal intestine (400 mg over 5 hours)
Study: 8592675
Drug: Nefazodone (NEF)
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nefazodone (NEF) administered orally (10 divided doses over 4.5 hours)
Study: 793781
Drug: Nethaprin Dospan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nethaprin Dospan (active drug)
Study: 31155953
Drug: Broccoli sprout
Normalized name: BROCCOLI SPROUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprout extract (BSE) 200 µmol daily
Study: 30385101
Drug: Narrative Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Medicine (NM) workshop
Study: 28777758
Drug: Exenatide 2mg
Normalized name: EXENATIDE 2MG/VIL INJ SA SUSP
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide 2mg (Bydureon) administered via once-weekly subcutaneous injections for 48 weeks
Study: 24585506
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg orally daily
Study: 22211733
Drug: Basal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal plus 3.5 g l-Lys/kg diet (T2)
Study: 22211733
Drug: Basal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal plus 1.5 g l-Leu/kg diet (T3)
Study: 22211733
Drug: Basal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal plus 3.5 g l-Lys plus 1.5 g l-Leu/kg diet (T4)
Study: 19957624
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine from lot 1
Study: 19957624
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine from lot 2
Study: 19957624
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine from lot 3
Study: 19957624
Drug: Licensed control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed control vaccine
Study: 31112203
Drug: Unmodified α‐1,3‐glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmodified α‐1,3‐glucan solution
Study: 28716797
Drug: Regular low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regular low-dose extended-release morphine
Study: 28716797
Drug: Upward titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upward titration of morphine after initial benefit
Study: 26036212
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen at 0.625 mg/d (n=5279)
Study: 17650793
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of Ginkgo biloba (EGb) given additionally to routine treatment for 2 months.
Study: 17650793
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (control group).
Study: 2500070
Drug: PSK (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSK (oral) in addition to mitomycin C and 5-FU for over 3 years
Study: 5306538
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cholera vaccine
Study: 5306538
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of cholera vaccine at an interval of 1 month
Study: 5306538
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of cholera vaccine
Study: 22964356
Drug: Adenosine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (1.2 mmol/L)
Study: 18205730
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group consuming high amounts of six selected vegetables (target of 350 g/day for 65 days)
Study: 16415629
Drug: Reality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reality therapy program
Study: 27358210
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg and 140 mg
Study: 25298573
Drug: Boswellia serrata
Normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia serrata (125 mg, 2 capsules)
Study: 22616314
Drug: Fixed ratio
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed ratio of morphine and oxycodone combinations (MOX) at ratios 3:2 in study A and 1:2 in study B
Study: 22616314
Drug: Fixed ratio
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed ratio of morphine and oxycodone combinations (MOX)
Study: 22616314
Drug: Morphine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine monotherapy
Study: 17589281
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral therapy plus sibutramine
Study: 17589281
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral therapy plus placebo
Study: 17589281
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (regardless of intervention)
Study: 17589281
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral therapy plus sibutramine (Caucasian group)
Study: 17589281
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral therapy plus sibutramine (African American group)
Study: 11880813
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of power and stretch training (PS)
Study: 4467872
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate tablets, BP, given before meals
Study: 4467872
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate tablets, BP, given after meals
Study: 4467872
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulation of ferrous salts
Study: 4467872
Drug: Liquid iron
Normalized name: Liquid Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid iron preparation
Study: 24008808
Drug: Brimonidine-timolol fixed
Normalized name: brimonidine / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine-timolol fixed combination
Study: 21498674
Drug: O-FC (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-FC (both doses)
Study: 15982795
Drug: 0.2% citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% citric acid solution (positive control)
Study: 12818970
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal treatment with mupirocin
Study: 10977438
Drug: Oral cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cefuroxime axetil
Study: 8875535
Drug: TPN supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN supplemented with 10 mg of iron as iron dextran daily (group 2)
Study: 1671884
Drug: Ditiocarb sodium
Normalized name: Ditiocarb zinc
DrugBank: Ditiocarb (DB02520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ditiocarb sodium (400 mg/m2 orally for 24 weeks)
Study: 29576447
Drug: Telephone support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone support for breastfeeding (weekly for 2 months, then every 2 weeks until 6 months)
Study: 20659762
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg aspirin daily for two months
Study: 20659762
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg aspirin daily for two months
Study: 20659762
Drug: Chronic ASA
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic ASA therapy
Study: 15855578
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nateglinide
Study: 15855578
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg nateglinide
Study: 11923801
Drug: Combined Azimilide
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Azimilide (100 and 125 mg)
Study: 10615220
Drug: Parsley intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsley intervention (3.73‐4.49 mg apigenin/MJ)
Study: 7793179
Drug: Succinylcholine 1.0‐1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.0‐1.5 mg kg‐1
Study: 20109071
Drug: Sorafenib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 100 mg BID
Study: 20109071
Drug: Sorafenib 200
Normalized name: sorafenib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 200 mg BID
Study: 20109071
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg BID
Study: 20109071
Drug: Sorafenib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 300 mg continuous
Study: 20109071
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg continuous
Study: 18817605
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1 mg/kg.day) for 3 days
Study: 15311643
Drug: Antibiotic levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic levels drawn from a central venous catheter (CVC)
Study: 15311643
Drug: Antibiotic levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic levels drawn from a peripheral vein
Study: 1303482
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg and 10 mg)
Study: 4074113
Drug: Therapy group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy group (including insight-oriented and current events)
Study: 28116430
Drug: Essential periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Essential periodontal treatment + routine maintenance therapy (Group A)
Study: 28116430
Drug: Routine maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine maintenance therapy (Group B)
Study: 28116430
Drug: Essential periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Essential periodontal treatment (Group C)
Study: 22938760
Drug: Oral antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotic treatment
Study: 1337708
Drug: Estraderm TTS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estraderm TTS, a 17 beta‐estradiol, administered for 11 weeks (3 cycles of 3 weeks treatment followed by 1 week therapy-free)
Study: 1337708
Drug: Premarin, consisting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin, consisting of conjugated estrogens, administered for 11 weeks (3 cycles of 3 weeks treatment followed by 1 week therapy-free)
Study: 3090962
Drug: Urokinase 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase 2000 U/kg/h for 24 hours with heparin (Group I: 18 patients)
Study: 3090962
Drug: Urokinase 4500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase 4500 U/kg/h for 12 hours without heparin (Group II: 47 patients)
Study: 3090962
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose urokinase group (Group II)
Study: 24861836
Drug: Craniosacral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniosacral therapy (one-time intervention)
Study: 19841157
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium gel 1% (16 g gel applied as 4 g to 1 knee 4 times daily)
Study: 19841157
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium gel 1% (48 g gel applied as 4 g per knee 4 times daily to 2 knees plus 2 g gel per hand applied 4 times daily to 2 hands)
Study: 19841157
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac sodium (150 mg oral diclofenac applied as 50-mg tablets 3 times daily)
Study: 19841157
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium gel 1%
Study: 19841157
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac sodium
Study: 17658120
Drug: Proprietary fractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary fractionated white bean extract (1000 mg, twice a day before meals)
Study: 11048457
Drug: ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (8 mg in 4 mL i.v.)
Study: 11048457
Drug: placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (4 mL saline i.v.)
Study: 8750569
Drug: Diltiazem, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 60 mg twice a day for 30 days
Study: 8750569
Drug: Diltiazem with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem with propylthiouracil, 100 mg three times a day for the last 20 days
Study: 4008675
Drug: Pramiracetam 400
Normalized name: aniracetam
DrugBank: Aniracetam (DB04599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramiracetam 400 mg
Study: 4008675
Drug: Pramiracetam 800
Normalized name: piracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramiracetam 800 mg
Study: 4008675
Drug: Pramiracetam 1200
Normalized name: piracetam 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramiracetam 1200 mg
Study: 4008675
Drug: Pramiracetam 1600
Normalized name: aniracetam
DrugBank: Aniracetam (DB04599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramiracetam 1600 mg
Study: 30582717
Drug: Calcipotriol (50 μg/g)
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam
Study: 30582717
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% cream
Study: 30582717
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 0.1% cream
Study: 30582717
Drug: Hydrocortisone-17-butyrate 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone-17-butyrate 0.1% ointment
Study: 19092238
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin infusion (50 IU insulin in 50 ml 0.9% saline solution applied intravenously via a perfusor pump)
Study: 19092238
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (insulin subcutaneously if concentrations were above 11.10 mmol/l)
Study: 12630984
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once daily for 9 days
Study: 3504725
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) injection of synthetic salmon calcitonin (SSCT) 80 IU
Study: 29384933
Drug: Video laryngoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video laryngoscopic guidance in the left lateral position (Group L)
Study: 20853007
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone for 10 days followed by oral cephalexin for 3 months (Control)